Skip to content

Revive Toric RWE Study

Samfilcon B Custom Toric Lens Real-World Observational Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06785194
Enrollment
30
Registered
2025-01-21
Start date
2026-05-31
Completion date
2026-07-31
Last updated
2025-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Astigmatism

Brief summary

This is a post-market observational clinical investigation. The objective of this observational study is to evaluate the visual performance and HCP satisfaction of REVIVE samfilcon B custom toric contact lenses.

Interventions

DEVICEREVIVE samfilcon B custom toric contact lenses

REVIVE samfilcon B custom toric contact lenses

Sponsors

Bausch & Lomb Incorporated
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

1. Be 18 years or older on the date the ICF is signed 2. Have the capacity to read, understand, and provide written voluntary informed consent 3. Have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings 4. Have no active ocular disease or allergic conjunctivitis 5. Not be using any topical ocular medications 6. Be willing and able to follow instructions 7. Have signed a statement of informed consent 8. Be an experienced soft contact lens wearer (have previously used soft contact lenses) 9. Meet the indications per the Instructions for Use (IFU) and have a suitable prescription for treatment with the device

Exclusion criteria

1. Is participating in another research study 2. Is considered by the Investigator to not be a suitable candidate for participation 3. Is not eligible for treatment with the study lens per the IFU (contraindicated) 4. Has had previous ocular surgery 5. Is taking/using ocular, systemic, or topical medications that, in the Investigator's opinion, could potentially affect ocular physiology or lens/solution performance

Design outcomes

Primary

MeasureTime frameDescription
Investigator overall satisfaction as assessed by the Investigator SurveyAssessed 14 days ± 3 days after the final dispensing/refinement visit(completed by the Investigator for each subject at 14 days ± 3 days after the final dispensing/refinement visit)

Countries

United States

Contacts

Primary ContactMarjorie Rah
Marjorie.Rah@bausch.com585-413-6397
Backup ContactVictoria Panagakis
victoria.panagakis@panacea85.com+44 (0) 7967 756 504

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026